Bluedoor Private Wealth LLC Makes New Investment in Eli Lilly and Company $LLY

Bluedoor Private Wealth LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, Holdings Channel.com reports. The firm bought 1,402 shares of the company’s stock, valued at approximately $1,507,000.

Several other hedge funds have also recently bought and sold shares of the business. Spire Wealth Management boosted its holdings in Eli Lilly and Company by 2.2% during the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock valued at $29,789,000 after acquiring an additional 592 shares during the period. Coldstream Capital Management Inc. boosted its holdings in Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after acquiring an additional 8,659 shares during the period. Farther Finance Advisors LLC boosted its holdings in Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after acquiring an additional 7,338 shares during the period. Teachers Retirement System of The State of Kentucky boosted its holdings in Eli Lilly and Company by 3.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock valued at $126,022,000 after acquiring an additional 5,595 shares during the period. Finally, Somerville Kurt F boosted its holdings in Eli Lilly and Company by 27.5% during the third quarter. Somerville Kurt F now owns 9,232 shares of the company’s stock valued at $7,044,000 after acquiring an additional 1,990 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 0.6%

NYSE LLY opened at $1,122.47 on Wednesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The firm has a 50-day simple moving average of $1,006.08 and a 200 day simple moving average of $1,016.63. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,182.73. The stock has a market cap of $1.06 trillion, a PE ratio of 39.87, a PEG ratio of 1.23 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter last year, the company earned $3.34 earnings per share. The firm’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly acquired 4E Therapeutics, a developer of non-opioid pain treatments, expanding its push into the painkiller market and broadening the company beyond obesity and diabetes drugs. Article Title
• Positive Sentiment: The company announced several pipeline updates, including progress on oral and early-stage candidates and a Phase 1 Alzheimer’s program, reinforcing investor focus on Lilly’s deep R&D pipeline. Article Title
• Positive Sentiment: Market research highlighting strong growth in the global GLP-1 receptor agonist market supports the long-term demand outlook for Lilly’s obesity and diabetes franchise, which remains a key driver of the stock. Article Title
• Neutral Sentiment: Healthcare stocks were generally firmer in afternoon trading, providing a modest sector tailwind rather than a company-specific catalyst. Article Title
• Neutral Sentiment: Several articles compared Lilly with Novo Nordisk amid ongoing obesity-drug competition, but these were mostly industry commentary and not new fundamental news for LLY. Article Title
• Negative Sentiment: Investors are also weighing a “quiet new threat” to Lilly’s GLP-1 business, as employer coverage and access concerns could slow adoption or limit growth for its top-selling obesity drugs. Article Title

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Royal Bank Of Canada restated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a report on Friday, June 5th. Berenberg Bank upped their price target on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a report on Thursday, February 19th. HSBC cut shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their price target for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Finally, Guggenheim restated a “buy” rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,227.74.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.